Sorrento Therapeutics Inc Sorrento’s (NASDAQ: SRNE) Subsidiary Scilex Gets an sNDA Approval for ZTlido Sorrento Therapeutics, Inc. (NASDAQ: SRNE) disclosed that Scilex Holding has got a supplemental new drug application (sNDA) authorization from the FDA for ZTlido. Scilex is the 99% owned unit of Sorrento Therapeutics.
